"The voice for cancer physicians and their patients in Massachusetts."

FDA Grants Accelerated Approval to zanubrutinib (Brukinsa) for mantle cell lymphoma

15 Nov 2019 2:24 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa; BeiGene) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software